{
    "1633891147121582080": {
        "attachments": {
            "media_keys": [
                "3_1633891136845561870"
            ]
        },
        "author_id": "5383942",
        "created_at": "2023-03-09T18:03:00.000Z",
        "edit_history_tweet_ids": [
            "1633891147121582080"
        ],
        "entities": {
            "annotations": [
                {
                    "end": 257,
                    "normalized_text": "GSKAnnualReport",
                    "probability": 0.6209,
                    "start": 243,
                    "type": "Other"
                }
            ],
            "hashtags": [
                {
                    "end": 5,
                    "start": 0,
                    "tag": "News"
                },
                {
                    "end": 16,
                    "start": 10,
                    "tag": "Media"
                },
                {
                    "end": 31,
                    "start": 21,
                    "tag": "Investors"
                },
                {
                    "end": 258,
                    "start": 242,
                    "tag": "GSKAnnualReport"
                }
            ],
            "urls": [
                {
                    "display_url": "pic.twitter.com/9CMyeLKA5t",
                    "end": 282,
                    "expanded_url": "https://twitter.com/GSK/status/1633891147121582080/photo/1",
                    "media_key": "3_1633891136845561870",
                    "start": 259,
                    "url": "https://t.co/9CMyeLKA5t"
                }
            ]
        },
        "id": "1633891147121582080",
        "lang": "en",
        "public_metrics": {
            "bookmark_count": 0,
            "impression_count": 5883,
            "like_count": 24,
            "quote_count": 0,
            "reply_count": 5,
            "retweet_count": 2
        },
        "text": "#News for #Media and #Investors\nWe\u2019re publishing our Annual Report tomorrow. In 2022 we\nbecame a focused global biopharma uniting science, technology and talent with the aim to positively impact the health of 2.5bn people by the end of 2030.\n#GSKAnnualReport https://t.co/9CMyeLKA5t"
    }
}